MEDICA 2025 Participation — Global Market Validation and Partnership Expansion
We verified overseas marketability and expanded partner networking by participating in MEDICA 2025 in Germany. We expanded discussions based on GMSM demonstration and application scenarios.
Hello, this is the WALK101 Newsletter.
In this issue, we share how WALK101 participated in MEDICA 2025 in Germany and verified the demand and applicability of the product in the global market on-site. Overseas expansion is not achieved solely through 'promotion'. The key is to lower barriers to adoption and crystalize partnerships based on field feedback.
Points confirmed at the MEDICA site
- ► The core criterion for adoption decision from the perspective of overseas hospitals/partners is 'PACS integration availability'
- ► Clear demands regarding the reliability (accuracy) of measurement values for AI results and the integration/application method with clinical workflows
- ► Many inquiries regarding analysis extensibility by body part and operation format (SaaS vs On-prem)
What was shown at the booth
At the booth, WALK101 introduced the product assuming actual adoption environment scenarios, centering on the demo of GMSM, an AI-based X-ray image analysis software. Rather than simply showing the 'result screen', we concretely conveyed field applicability by presenting the flow (integration method) from image input to result provision.
Global Expansion Strategy Perspective
The purpose of participating in MEDICA is clear. It is to quickly confirm the 'essential requirements' of the market, adjust the product/operation format to suit the field, secure a partner network, and create a path leading to local adoption. WALK101 continues to strengthen the 'Integrated AI' experience that works even in global environments.